Antibodies to OPGL

What is this patent about?

’736 is related to the field of bone metabolism and therapeutic antibodies, specifically targeting the regulation of bone resorption. In healthy skeletal tissue, a dynamic equilibrium exists between bone formation by osteoblasts and bone destruction by osteoclasts. However, in conditions such as osteoporosis, rheumatoid arthritis, and Paget's disease, this balance shifts toward excessive resorption. The patent addresses the need for targeted molecular therapies that can inhibit the cellular signaling pathways responsible for the over-activation of bone-dissolving cells.

The underlying idea behind ’736 is to neutralize the osteoprotegerin ligand (OPGL), a critical cytokine that triggers the maturation and activation of osteoclasts. By binding to its receptor, RANK, OPGL acts as the primary signal for bone breakdown. The invention utilizes a high-affinity, fully human monoclonal antibody to act as a decoy antagonist, mimicking the natural regulatory function of osteoprotegerin (OPG). By sequestering OPGL, the antibody prevents it from engaging its receptor, thereby effectively halting the signal transduction cascade that leads to pathological bone loss.

The claims of ’736 focus on the specific molecular structure of the antibody, defined by its amino acid sequences. The independent claims cover isolated antibodies comprising heavy and light chains identified by SEQ ID NO: 2 and SEQ ID NO: 4, as well as their respective variable regions (SEQ ID NO: 13 and 14). Furthermore, the claims encompass antibodies defined by the specific complementarity determining regions (CDRs) found within these variable regions, which are the precise segments responsible for the antibody's high-affinity binding to the OPGL protein.

In practice, the antibody is produced using recombinant DNA technology, typically expressed in mammalian cell lines like CHO cells to ensure proper folding and activity. Once administered, the antibody circulates and binds to both soluble and membrane-bound OPGL. Engineering data shows that this binding is highly specific; the antibody does not interact with other related TNF family members like TRAIL or CD40 ligand. This target specificity is crucial for minimizing off-target effects while achieving a potent reduction in bone resorption markers, such as N-telopeptide, within hours of administration.

The invention differs from prior approaches, such as bisphosphonates or hormone therapies, by providing a biological mechanism that directly intercepts the RANK/RANKL signaling pathway. Unlike traditional chemical agents that may have systemic side effects or limited efficacy in severe osteolytic conditions, this fully human antibody is designed to be less immunogenic and more potent. By precisely blocking the ligand responsible for osteoclast differentiation, the ’736 invention provides a highly targeted means of restoring skeletal equilibrium in patients with diverse bone-wasting disorders.